The Minister of Science explains that the studies carried out to date point to good efficacy against the different variants of the coronavirus
The vaccine against covid-19 developed by the Spanish pharmaceutical company Hipra “presents good results compared to the omicron variant“, as confirmed this Tuesday by the Minister of Science and Innovation, Diana Morant, after visiting the company’s facilities in Girona. The minister has also confirmed that, as advanced by EL PERIÓDICO, the formula will soon move to the third phase of clinical trials and, if clinical trials are successful, the injection could be commercialized in the second quarter of the year.
At the moment, as explained by the minister, clinical studies suggest that “there is no doubt about safety and efficacy of this vaccine in people “, so it is expected that the Spanish Medicines Agency will shortly authorize the start of the last phase of clinical trials. At this stage, prior to the marketing of the drug, the injection will be tested in 3,000 volunteers as a third dose against covid-19. The study will be carried out in 18 hospitals in Spain and will also be extended to various institutions of Portugal, Italy and Vietnam.
As Elia Torroella, director of Hipra’s research and records department, explained to this newspaper a few days ago, the forecast is that “the last phase of clinical studies will begin in January. Between February and MarchWhen we have the safety and efficacy data, we will ask for your authorization. Hipra’s vaccine could be approved by the second quarter of 2022. Then, we estimate that we will have already produced 600 million doses and we will be prepared to deliver vaccines as soon as requested. ”
“A year of hope”
This Tuesday, after a visit to the Hipra facilities, Morant stressed that at the moment both Spain and Europe have their hopes pinned in the formula developed by this Girona pharmacist. “I would like it to be the year of Hipra,” declared the minister during an appearance before the media held at the doors of the company. Along the same lines, Morant has also expressed the wish that 2022 be a “year of hope in overcoming the pandemic“and in the recovery of its” socioeconomic derivatives. “
Related news
During his speech, Morant has argued that the goal of this project is to get a “Spanish vaccine and improve existing ones“Especially after the Government has accompanied the Catalan company” from the first moment “, both through scientific advice and in the contribution of spaces such as hospitals to carry out tests and advice on regulatory matters. all this has been added financing, “with a first grant of three million euros for research and one second of fifteen million more which is making the company have production capacity. ”
Given the success of this project, Morant has also assured that “the axis of the future will be public-private collaboration“As in the case of Hipra. In relation to this, the Minister of Science has also announced that 2 million euros will be invested leading a consortium of companies to research an advanced therapy aimed at make a vaccine against “a virus that causes bronchiolitis and pneumonia in all ages, but especially in very young children.”
Reference-www.elperiodico.com